PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis

  1. 1. PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecastand Market AnalysisReport Details:Published:November 2012No. of Pages: 83Price: Single User License – US$4995PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market AnalysisSummaryGlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines ItalyDrug Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused byinfluenza virus that results in mild to severe symptoms, such as fever, cold and cough. The marketis heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently,trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarixand FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with theentrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMistand Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption ofsuch vaccines over the traditional intramuscular vaccines. GlobalData also anticipates thatmanufacturers that launch quadrivalent formulations will steal market share, patient share, andrevenue from the trivalent influenza vaccines currently available.The Italian influenza vaccine market is valued at approximately $55.8m in 2012. The expecteddrivers of growth include the launch of quadrivalent influenza vaccines and an increase in theelderly population.The market leaders are Novartis’ adjuvanted trivalent influenza vaccines, Fluad and InflupozziAdiuvato. The squalene adjuvant in these vaccines boosts the immune response of elderlyrecipients, who often fail to get adequately immunized by typical influenza vaccines. This improvedimmunogenicity has allowed Fluad and Influpozzi Adiuvato to harness a large share of the elderlymarket in Italy.Scope- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis,
  2. 2. pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in Italy including product description, safety and efficacyprofiles as well as a SWOT analysis.- Sales forecast for the top drugs in Italy from 2012 to 2022.- Analysis of the impact of key events as well the drivers and restraints affecting the Italy seasonalinfluenza market.Reasons to buy- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape forseasonal influenza- Effectively plan your M&A and partnership strategies by identifying drugs with the most promisingsales potential- Make more informed business decisions from insightful and in-depth analysis of drugperformance- Obtain sales forecast for drugs from 2012 to 2022 in Italy.Get your copy of this report @ points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 41.1 List of Tables 61.2 List of Figures 62 Introduction 72.1 Catalyst 72.2 Related Reports 73 Disease Overview 103.1 Etiology and Pathophysiology 103.1.1 Etiology 103.1.2 Pathophysiology 143.2 Symptoms 153.3 Prognosis 154 Disease Management 164.1 Influenza Vaccination Policy 164.2 Italy 174.2.1 Influenza Vaccination Recommendations and Policies 174.2.2 Clinical Practice 185 Competitive Assessment 195.1 Overview 19
  3. 3. 5.2 Strategic Competitor Assessment 195.3 Product Profiles - Major Brands 225.3.1 Fluarix/FluLaval 225.3.2 FluMist 265.3.3 Vaxigrip/Mutagrip 295.3.4 Influvac 335.3.5 Fluad 365.3.6 Agrippal 395.3.7 Optaflu 426 Opportunity and Unmet Need 476.1 Overview 476.2 Unmet Needs 486.2.1 Higher level of patient awareness 486.2.2 Increased efficacy in the elderly and young children (6.2.3 Improved vaccine side-effectprofiles 496.2.4 More efficient vaccine manufacturing process 496.2.5 More cost-effective vaccines 496.3 Gap Analysis 506.4 Opportunities 516.4.1 Expanded breadth of protection against viral strains 516.4.2 Increased duration of protection 516.4.3 T-cell involvement 527 Pipeline Assessment 537.1 Overview 538 Market Outlook 548.1 Italy 548.1.1 Forecast 548.1.2 Key Events 588.1.3 Drivers and Barriers 599 Appendix 619.1 Bibliography 619.2 Abbreviations 709.3 Methodology 719.4 Forecasting Methodology 719.4.1 Vaccine Coverage 719.4.2 Vaccines Included 729.4.3 Key Launch Dates 739.4.4 Influenza Vaccine Tender System Assumptions 749.4.5 General Pricing Assumptions 749.4.6 Individual Vaccine Assumptions 759.5 Physicians and Specialists Included in this Study 799.6 Primary Research - Prescriber Survey 80
  4. 4. 9.7 About the Authors 819.7.1 Authors 819.7.2 Global Head of Healthcare 829.8 About GlobalData 839.9 Contact Us 839.10 Disclaimer 831.1 List of TablesTable 1: Notable Influenza Pandemics 14Table 2: Symptoms of Influenza 15Table 3: Influenza Vaccination Recommendation Committees by Country 16Table 4: Leading Influenza Vaccines, 2012 21Table 5: Product Profile - Fluarix 23Table 6: Fluarix SWOT Analysis, 2012 25Table 7: Product Profile - FluMist 27Table 8: FluMist SWOT Analysis, 2012 29Table 9: Product Profile - Vaxigrip 30Table 10: Laboratory-Confirmed Influenza Infection Rates in Vaccine or Placebo Recipients andtheir Household Contacts 31Table 11: Vaxigrip SWOT Analysis, 2012 32Table 12: Product Profile - Influvac 33Table 13: Influvac SWOT Analysis, 2012 35Table 14: Product Profile - Fluad 36Table 15: Fluad SWOT Analysis, 2012 39Table 16: Product Profile - Agrippal 40Table 17: Agrippal SWOT Analysis, 2012 42Table 18: Product Profile - Optaflu 43Table 19: Optaflu SWOT Analysis, 2012 46Table 20: Overall Unmet Needs - Current Level of Attainment 47Table 21: Clinical Unmet Needs - Gap Analysis, 2012 51Table 22: Sales Forecasts ($m) for Influenza Vaccines in Italy, 2012-2022 56Table 23: Key Events Impacting Sales of Influenza Vaccines in Italy, 2012 58Table 24: Influenza Vaccine Market - Drivers and Barriers, 2012 59Table 25: Key Launch Dates 73Table 26: Physicians Surveyed, By Country 801.2 List of FiguresFigure 1: Influenza Virus Structure 10Figure 2: Sales for Influenza Vaccines in Italy by Route of Administration, 2012-2022 57Contact: for more information.